X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Data from Phase 3 VAT08 and VAT02 efficacy study showed that two doses of Sanofi-GSK booster vaccine SP0253 or GSK4353001A (SARS-CoV-2 recombinant protein vaccine) generated an efficacy of 100%, 75%, 57.9% against severe COVID-19 disease.
Lead Product(s): SARS-CoV-2 Recombinant Protein Vaccine,AS03
Therapeutic Area: Infections and Infectious Diseases Product Name: SP0253
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2022
RDD 2024
Not Confirmed
Contact SupplierDetails:
SKYCovion contains nanoparticles of recombinant Receptor Binding Domain (RBD) of SARS-CoV-2 Spike (S) protein from the parental D614G strain and an adjuvant system (AS03) and got approval by MHRA for treating COVID-19 infection.
Lead Product(s): Recombinant Adjuvanted Covid-19 Vaccine,AS03
Therapeutic Area: Infections and Infectious Diseases Product Name: SKYCovion
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2023
Details:
Apart from Canada regulatory filing has also been initiated for USFDA and MHRA for CoVLP (Recombinant Coronavirus Virus-Like Particle COVID-19 vaccine), the first-ever plant-based vaccine, final portion of data submitted as part of New Drug Submission COVID rolling review.
Lead Product(s): Recombinant Coronavirus Virus-Like Particle COVID-19 vaccine,AS03
Therapeutic Area: Infections and Infectious Diseases Product Name: CoVLP
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2021
Details:
Covid19 Vaccine candidate demonstrated efficacy against all variants seen in the study, including 75.3% efficacy against COVID-19 of any severity caused by the globally dominant Delta variant.
Lead Product(s): CoVLP Adjuvanted Vaccine,AS03
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2021
Details:
The Phase 3 portion is an event-driven, randomized, observer-blinded, crossover placebo-controlled design that will evaluate the efficacy and safety of the CoVLP formulation, compared to placebo, in up to 30,000 subjects.
Lead Product(s): Recombinant Coronavirus Virus-Like Particle COVID-19 vaccine,AS03
Therapeutic Area: Infections and Infectious Diseases Product Name: CoVLP
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2021
Details:
Medicago’s plant-derived vaccine candidate against COVID-19 uses Coronavirus-Like-Particle (CoVLP) technology with the vaccine composed of recombinant spike (S) glycoprotein expressed as virus-like-particles (VLPs) co-administered with GSK’s pandemic adjuvant.
Lead Product(s): Recombinant Coronavirus Virus-Like Particle COVID-19 vaccine,AS03
Therapeutic Area: Infections and Infectious Diseases Product Name: CoVLP
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2021
Details:
Anvisa said the companies were authorized to conduct phase 3 trials in the country. The companies are planning to test the new vaccines in around 30,000 people, in the U.S., Canada, Europe and Latin America. Brazil may have around 3,500 volunteers for the trials.
Lead Product(s): Recombinant Coronavirus Virus-Like Particle COVID-19 vaccine,AS03
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2021
Details:
Medicago's plant-derived vaccine candidate against COVID-19 uses Coronavirus-Like-Particle (CoVLP) technology with the vaccine composed of recombinant spike (S) glycoprotein expressed as virus-like-particles (VLPs) co-administered with GSK's pandemic adjuvant.
Lead Product(s): Recombinant Coronavirus Virus-Like Particle COVID-19 vaccine,AS03
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2021
Details:
CH8/1N1 LAIV produced a strong, functional immune response with cross-reactive antibodies targeting the hemagglutinin stalk domain, which were detectable for at least 18 months following vaccination in 65 healthy, 18 to 39-year-old US participants.
Lead Product(s): CH8/1N1 LAIV,AS03
Therapeutic Area: Infections and Infectious Diseases Product Name: CH8/1N1 LAIV
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2020
Details:
Clover’s protein-based COVID-19 vaccine candidates adjuvanted with either GSK’s pandemic adjuvant system or Dynavax’s CpG 1018 plus alum induced strong neutralizing immune responses in 150 adult and elderly subjects from the Phase 1 clinical study.
Lead Product(s): Adjuvanted COVID-19 S-Trimer vaccine,AS03,CpG-1018
Therapeutic Area: Infections and Infectious Diseases Product Name: SCB-2019
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 04, 2020
Details:
The results of the trial demonstrated that 100 per cent of subjects developed a promising antibody response after two doses of Medicago’s COVID-19 adjuvanted vaccine candidate.
Lead Product(s): Recombinant Coronavirus Virus-Like Particle COVID-19 vaccine,AS03
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.
Lead Product(s): AS03,Recombinant protein-based vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Xiamen Innovax Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 03, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
